Skip to content
Zeposia(ozanimod)
Zeposia (ozanimod) is a small molecule pharmaceutical. Ozanimod was first approved as Zeposia on 2020-03-25. It is used to treat relapsing-remitting multiple sclerosis in the USA. It has been approved in Europe to treat relapsing-remitting multiple sclerosis and ulcerative colitis. The pharmaceutical is active against sphingosine 1-phosphate receptor 1 and sphingosine 1-phosphate receptor 5. In addition, it is known to target sphingosine 1-phosphate receptor 2, sphingosine 1-phosphate receptor 4, and sphingosine 1-phosphate receptor 3.
Download report
Favorite
FDA Novel Drug Approvals 2020
BMS
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
digestive system diseasesD004066
nervous system diseasesD009422
immune system diseasesD007154
Trade Name
FDA
EMA
Zeposia
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ozanimod hydrochloride
Tradename
Company
Number
Date
Products
ZEPOSIACelgeneN-209899 RX2020-03-25
3 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
zeposia zeposia New Drug Application2020-09-01
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
relapsing-remitting multiple sclerosisEFO_0003929D020529
Agency Specific
FDA
EMA
Expiration
Code
OZANIMOD HYDROCHLORIDE, ZEPOSIA, CELGENE INTL
2025-03-25NCE
2024-05-27I-860
Patent Expiration
Patent
Expires
Flag
FDA Information
Ozanimod Hydrochloride, Zeposia, Celgene Intl
102398462030-11-15U-3132
84815732029-05-14DS, DPU-2774
87963182029-05-14DS, DP
93822172029-05-14U-2774
ATC Codes
L: Antineoplastic and immunomodulating agents
L04: Immunosuppressants
L04A: Immunosuppressants
L04AA: Selective immunosuppressants
L04AA38: Ozanimod
HCPCS
No data
Clinical
Clinical Trials
38 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Ulcerative colitisD003093EFO_0000729K5125129
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple sclerosisD009103EFO_0003885G351326
Crohn diseaseD003424EFO_0000384K50256
Relapsing-remitting multiple sclerosisD020529EFO_00039291213
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Covid-19D000086382U07.111
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients9110
Liver diseasesD008107EFO_0001421K70-K7711
Digestive system diseasesD004066EFO_0000405K92.911
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Medication adherenceD055118EFO_000634411
FatigueD005221HP_0012378R53.8311
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameOZANIMOD
INNozanimod
Description
Ozanimod, sold under the brand name Zeposia, is an immunomodulatory medication for the treatment of relapsing multiple sclerosis and ulcerative colitis. It acts as a sphingosine-1-phosphate (S1P) receptor agonist, sequestering lymphocytes to peripheral lymphoid organs and away from their sites of chronic inflammation.
Classification
Small molecule
Drug classimmunomodulators
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(C)Oc1ccc(-c2nc(-c3cccc4c3CC[C@@H]4NCCO)no2)cc1C#N
Identifiers
PDB
CAS-ID1306760-87-1
RxCUI2288236
ChEMBL IDCHEMBL3707247
ChEBI ID
PubChem CID52938427
DrugBankDB12612
UNII IDZ80293URPV (ChemIDplus, GSRS)
Target
Agency Approved
S1PR1
S1PR1
S1PR5
S1PR5
Organism
Homo sapiens
Gene name
S1PR1
Gene synonyms
CHEDG1, EDG1
NCBI Gene ID
Protein name
sphingosine 1-phosphate receptor 1
Protein synonyms
CD363, Endothelial differentiation G-protein coupled receptor 1, endothelial differentiation, sphingolipid G-protein-coupled receptor, 1, S1P receptor 1, S1P receptor Edg-1, Sphingosine 1-phosphate receptor Edg-1, sphingosine 1-phosphate receptor EDG1
Uniprot ID
Mouse ortholog
S1pr1 (13609)
sphingosine 1-phosphate receptor 1 (Q9R235)
Alternate
S1PR2
S1PR2
S1PR4
S1PR4
S1PR3
S1PR3
Organism
Homo sapiens
Gene name
S1PR2
Gene synonyms
EDG5
NCBI Gene ID
Protein name
sphingosine 1-phosphate receptor 2
Protein synonyms
CTD-2369P2.2, deafness, autosomal recessive 68, Endothelial differentiation G-protein coupled receptor 5, endothelial differentiation, sphingolipid G-protein-coupled receptor, 5, S1P receptor 2, S1P receptor Edg-5, S1P receptor EDG5, Sphingosine 1-phosphate receptor Edg-5
Uniprot ID
Mouse ortholog
S1pr2 (14739)
sphingosine 1-phosphate receptor 2 (Q9R236)
Variants
Clinical Variant
No data
Financial
Zeposia - Bristol Myers Squibb
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 799 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
11,365 adverse events reported
View more details